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Genetic association between DLA class II and Symmetrical lupoid onychodystrophy in giant 
schnauzer and bearded collie 
Charlotte Harlos 
Abstract 
Symmetrical lupoid onychodystrophy (SLO) is a disease that affects dogs at ages between 3 to 8 years. The 
dogs start to slough their claws and in a few weeks every claw on each paw is involved. The histological 
pattern of affected claws resembles other autoimmune diseases. The etiology of SLO is unknown but the 
symmetrical paw involvement and the histopathological pattern indicates that SLO might be an 
autoimmune disease.  
Alleles and haplotypes of the canine Major Histocompatibility Complex (MHC) class II has been associated 
with different kinds of autoimmune diseases.  MHC class II is in dog referred to the as dog leukocyte antigen 
(DLA) system: DLA-DRA, DLA-DRB1, DLA-DQA1 and DLA-DQB1. These genes are in high linkage 
disequilibrium and the DLA-DRB1, DLA-DQA1 and DLA-DQB1 genes are highly polymorphic.  
The aim with this study is to evaluate if there is a genetic association between the development of SLO or 
other claw problems and certain DLA alleles, haplotypes or genotypes.  
In Sweden studies have shown that SLO occur at higher frequency in giant schnauzer, schnauzer, bearded 
collie and Gordon setter.  In this study, 110 giant schnauzers and 10 bearded collies were examined. Each 
dog in this study was categorized in a group according to its claw problem and the sequence of polymorphic 
genes DLA-DRB1, DLA-DQA1 and DLA-DQB1 were determined. Statistical calculations were made to 
determine whether some allele, haplotype or genotype give rise to an increased risk for developing SLO or 
other claw problems. 
The results show that in giant schnauzer, haplotype DRB1*01301/DQA1*00301/DQB1*00501 and allele 
DRB1*01301 are protective against the development of claw problems, with a p-value of 0,001. The 
haplotype DRB1*00101/DQA1*00101/DQB1*00201 may give rise to an increased risk for developing 
different kinds of claw problems (frequency of control group 15% versus the case group 26, 9%), although 
this result is not statistically significant. Statistical analyses indicate that haplotype 
DRB1*01801/DQA1*00101/DQB1*00201 and allele DQB1*00201 may give rise to a higher risk of 
developing SLO in bearded collie, however too few individuals were analysed to give statistically significant 
results.  
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1. Introduction 
The domesticated purebred dog arose from two different canine population bottlenecks. The first 
bottleneck was created approximately 7.000- 50.000 generations ago when wolfs were domesticated; 
the second bottleneck is associated with the creation of different breeds, which started approximately 
50-100 generations ago. The breeding programmes of the purebred dog, which purpose is to select for 
different genetic variants, in order to obtain certain morphology, physiology or behaviour, have lead to a 
reduced polymorphism (i.e. genetic variation) (Lindblad-Toh et al., 2005). Several purebred dog breeds 
have shown a tendency to develop certain autoimmune diseases. An explanation to this can be the 
reduced genetic variation caused by the breeding programmes. Studies suggest that there are similar 
genetic factors between human and dog and also environmental factors, which humans and dogs share, 
that can contribute to the development of autoimmune diseases (Kennedy et al., 2007). 
 
The membrane bound glycoprotein encoded by Major Histocompatibility Complex (MHC), are located in 
three tightly linked regions of genes called class I, II and III (Kennedy et al., 2006). MHC class II has been 
shown to be involved in the development of autoimmune diseases in both human and dogs (Brand et al., 
2005) (Kennedy et al. 2006 68) (Kennedy et al. 2006 67) (Kennedy et al. 2007 69). The MHC in dog is 
referred to the dog leukocyte antigen (DLA) system. MHC class I and II molecules are involved in 
presenting self and non self antigens to T killer and T helper lymphocytes of the immune system. The 
genes of MHC class I and II are highly polymorphic, i.e. many different alleles at high frequency in the 
population, which differ at multiple positions corresponding to the domain encoding the antigen binding 
pocket. DLA class II in dog include three highly polymorphic genes which are known as DLA-DQB1, DLA-
DQA1 and DLA-DRB1 and one monomorphic gene known as DLA-DRA (Kennedy et al., 2006) (Debenham 
et al., 2005). There are at present 67 DLA-DRB1, 2 DLA-DQA1 and 54 DLA-DQB1 alleles (Kennedy et al., 
2006). 
 
In this study we will investigate dogs with different kinds of claw diseases. Some of the dogs have been 
diagnosed with the disease symmetrical lupoid onychodystrophy (SLO). SLO is a claw disease where 
otherwise healthy dogs start to slough their claws. It begins with one or two affected claws on a single 
paw and after a few weeks every claw on each paw is involved (Scott, et al. 1995). The etiology of SLO is 
unknown; histopathology of the affected claw resembles the histopathology of a number of autoimmune 
diseases, such as systemic and discoid lupus erythematosus, pemphigus and bullous pemphigoid (Scott, 
1982). 
 
The aim with this study is to determine whether certain DLA class II haplotypes, genotypes or alleles can 
be associated with the development of SLO or other claw problems. Blood samples from giant schnauzer 
and bearded collies have been examined as epidemiological studies have shown that these breeds are 
more predisposed to develop SLO (Ferm Katarina, http://hunddna.slu.se/artikelserie/BeardedCollie.pdf). 
In the future, the information concerning risk or protective DLA class II haplotypes, genotypes or alleles 
may be used to breed healthier dogs. 
 
2. Literature review 
2.1 Immunology 
The immune system is built up by both a nonspecific and a specific component. The nonspecific 
component, the innate immunity, includes different kinds of disease resistance mechanisms, which are 6 
 
not specific for a certain pathogen. In contrast, the specific components of the immune system, the 
adaptive immunity, show high degree of specificity to certain antigen/s. 
 
The adaptive immunity can be divided into a humoral immune response and a cellmediated response. In 
the cellmediated response a T cell binds to peptide antigens presented by a MHC class I molecule 
expressed on an altered self cell, typically a virus infected cell, and generate an active cytotoxic T 
lymphocyte response witch will cause cell lysis of the altered virally infected self cell. In the humoral 
immune response professional antigen-presenting cells such as dendritic cells, macrophages or activated 
B-cells interact with a foreign antigen, which will activate the B-cell. The antigen will be processed and 
presented on the B-cells cell membrane combined with a MHC II-molecule. A T-helper cell, that is specific 
for the antigen, will bind with its T-cell receptor (TCR) to the complex. This binding will activate the T 
helper cell, which will start to secrete cytokines. The cytokines will stimulate cell division and 
differentiation of the B-cell to an antigen producing plasma cell and memory cell. The antibodies will 
bind to the antigen and neutralize it or facilitate its elimination.  
 
The adaptive immune systems function is to eliminate foreign antigens and it is capable to discriminate 
between self and nonself. The T lymphocytes mature in thymus, when they start to express their antigen 
binding receptors (TCR) they are either positively or negatively selected. The positive selection takes 
place in the cortical region of the thymus and permits only survival of those T-cells that recognize self 
MHC molecules. The T-cell population that survived the positive selection will undergo the negative 
selection, where the T cells, which interact too strongly with the MHC molecules, or with the MHC 
molecule together with a self antigen, will be eliminated. Due to this selection process only T cells that 
recognize the MHC molecules and have an acceptable affinity for the MHC molecule and the MHC 
molecule plus self antigen, are allowed to mature. Like most biological processes this MHC restriction is 
incomplete and not all self reactive lymphocytes are deleted during T cells and B cells maturation, which 
can lead to autoimmunity. 
 
2.1.1 Autoimmunity 
Autoimmunity is the failure of the immune system to recognize what is self and what is non self of the 
organism and the immune system starts to attack the organisms own cells and/or tissue. Thus, the 
tolerance process described above may have been incomplete or alternatively, established central 
tolerance may have been broken as a result of a productive infection. The exact mechanisms responsible 
for developing an autoimmune disease are still unclear. However, the central importance for MHC 
molecules is well established. 
 
Autoimmune diseases can be divided into two general categories, the organspecific and the systemic. 
The organspecific is characterized by immune responses directed against antigens specific to a single 
organ or gland in the organism. This will either directly damage the cells of the organ or indirect by the 
humoral or cellmediated immune response. Antibodies produced by the humoral immune response may 
also over stimulate or under stimulate the normal function of the organ. A systemic disease is when the 
immune response is directed toward a variety of organs in the organism. This disease reflects a general 
defect of the immune system, which results in a widespread tissue damage (Goldsby R. A, Kindt T. J and 
Osborne B. A, 2001). 
 
2.2 The Major Histocompatibility Complex (MHC) 
MHC molecules are expressed by three tightly linked clusters of genes, called class I, II and III. The MHC 
contains several class I and class II genes that encode membrane bound glycoproteins. MHC class I 7 
 
molecules are expressed on virtually all nucleated cells, with the exception of neurons and certain gonad 
cells and germline cells. In contrast, MHC class II molecules are expressed by professional antigen 
presenting cells (B-cells, macrophages, dendritic cells and activated T-cells) in the immune system. The 
genes in the MHC in dogs are called the dog leukocyte antigen (DLA). The function of MHC class I and II is 
to present self and non self antigens to the immune system. Three genes within the DLA class II are 
highly polymorphic i.e. presence of multiple alleles at a given locus and are known as DLA-DRB1, DLA-
DQA1 and DLA- DQB1 and one gene known as DLA-DRA, appears to be monomorphic (Kennedy et al., 
2006) (Debenham et al., 2005). There are at present 67 DLA-DRB1, 2 DLA-DQA1 and 54 DLA-DQB1 alleles 
(Kennedy et al., 2006).  
 
Different haplotypes and alleles of DQA1, DQB1 and DRB1 genes have been shown to either protect or 
predispose for many different autoimmune diseases (Brand et al., 2005). In dog, several DLA class II 
alleles have been associated with different autoimmune diseases such as hypothyroidism (Wilbe et al. 
submitted) (Kennedy et al. 2006 67), immune-mediated anemia (Kennedy et al. 2006 68), diabetes 
mellitus (Kennedy et al. 2007 69). In humans, the MHC is referred to the human leukocyte antigen (HLA) 
system. The HLA class II are highly polymorphic and different class II molecules have been shown to be 
major risk factors in the development of several autoimmune diseases (Brand et al., 2005). Studies have 
shown that a conserved amino acid sequence in the hyper variable region present in some DRB1 alleles II 
in both human and dog is involved in higher susceptibility to develop rheumatoid arthritis (Ollier et al., 
2001), association has also been found between canine and human diabetes mellitus ( DQA1 Arg 52 in 
human and DQA1 Arg 55 canine). This indicates that there is a shared pathology and genetic 
susceptibility to develop certain autoimmune diseases in human and dogs (Kennedy et al. 2007). 
 
2.3 The Claw 
The claw is a specialized structure in the dog. Its function is to work as a prehensile and locomotion 
organ but also as a protection of underlying tissue. The claw is compressed laterally and can be divided 
into the lateral and medial walls, the sole (ventral) and the dorsal ridge of the coronary band. The distal 
phalanx has a dorsal process called the ungual crest; dermis is continuous with this dorsal process and 
continues distally as the periosteum of the distal phalanx. Dermis has many fine papillae that extend into 
the lamellae of the epidermis. The epidermis of the claw is supported by the dermis. The highest growth 
activity of the epidermal basal layer is found in the coronary and dorsal ridge areas. The epidermis of the 
claw sole has distinct granular and clear layers, compared to the epidermis of the rest of the claw, which 
is composed of a thick horny layer of flat cornified epidermal cells, fused into a horny plate with an 
absent stratum granulosum. 8 
 
Picture 1. Midsagital section of claw:  a: epidermis, c: dermis, l: ungual crest (Scott, Miller 1992) 
 
In human medicine, many systemic diseases have been associated with nail deformations. Examples of 
such diseases are psoriasis, epidermolysis bullosa, alopecia areata etc. Diseases associated with the claw 
in dogs are trauma, demodicosis, infections, pemphigus, viral infection, systemic lupus erythematosus, 
pemphigoid, vascular insufficiency, seborrheic dermatitis, acromegaly and senility.  
 
2.3.1 Disorders of the claw 
Paronychia: is an inflammation in the soft tissue around the claw. The inflammation is usually caused by 
bacteria (i.e. bacterial paronychia), but it is also caused by dermatophytes or yeast (Muller et al., 1989). 
When only a single claw is affected, it is likely due to a trauma (e.g. bite wound, crush injury, torn claw) 
(Scott, Miller 1992), but if multiple claws on multiple paws are involved it is likely due to an underlying 
systemic disease such as pemphigus, bullous pemphigoid, systemic lupus erythematosus, 
lymphosarcoma, generalized demodicosis or diabetes mellitus.  
 
Onychomycosis:  fungal infection usually caused by Trichophyton mentagrophytes. 
 
Onychorrhexis (brittle nails): when the nail breaks from the free edge, this occurs spontaneously in some 
dogs. When only a single claw is involved it is usually due to a trauma, but when several nails are 
involved on more than one paw the cause is unknown. 
 
Onychomadesis:  the hard keratin layer separate, this causes loss (slough) of the nail.  This can be caused 
by trauma, infection, vascular disorders or autoimmune disorders such as pemphigus and systemic lupus 
erythematosus. 
 
Miscellaneous: when the nails grow very rapidly and are abnormally thick, as in canine acromegaly and 
zinc responsive/deficient disorders (Muller et al., 1989).  
 
2.3.2 Symmetrical lupoid onychodystrophy (SLO) 
Symmetrical lupoid onychodystrophy is a disease that affects every claw on all paws in canines (Scott et 
al., 1995). Symmetrical paw involvement (i.e. all four paws) indicates a systemic disorder such as 
immune-mediated, endocrine, nutrial and/or immunosuppressive disease (Scott & Miller, 1992). The 
disease typically appears at an age of 3-8 years and male dogs have shown to be predisposed (Bohnhorst 
J. Ö et al., 2001). SLO have been reported to occur in a higher prevalence in German shepherds (Scott et 
al., 1995). In Sweden, studies have shown that SLO occur in a higher frequency in giant schnauzer, 
schnauzer, bearded collie and Gordon setter (Ferm Katarina, 
http://hunddna.slu.se/artikelserie/BeardedCollie.pdf).  
 
The disease is characterized by separation at the claw bed and sloughing of the claws (i.e. 
onychomadesis), sometimes a brown line at the claw bed is noticed, and this is likely due to hemorrhage 
prior to sloughing. Usually the owners discover one affected claw on one or two paws and within 2-9 
weeks every claw on all four paws are affected. Lameness and pain is seen in half of the cases, whereas 
the other half does not seem to be aware of their disease. The regrowth of the affected claws are 
characterized by short, soft, dry and very fragile misshapen (i.e. onychodystrophy) claws. Dogs with 
symmetrical lupoid onychodystrophy are otherwise in good health and do not show any other signs of 
other diseases (Scott et al., 1995).  
 9 
 
Surgical amputation of the third phalanx and histological examination of the claw bed is required to 
confirm diagnosis (Scott & Miller, 1992). Histopathology of affected claws present infiltrate of 
mononuclear cells, apoptosis of the epidermal basal cells and hydropic degeneration of the epidermal 
basal cells. The histological changes in dermis are characterized by edema, hemorrhage and fibrosis. The 
histopathological lesions are usually seen along the coronary band on the dorsal aspect of the claw. 
Typically the inflammatory infiltrate forms a parallel band to the basement membrane, this is called 
lichenoid pattern. Pigmentary incontinence is also often observed in the dermis (Scott et al., 1995). The 
inflammatory infiltrate is predominantly represented by B cells and T cells and macrophages are only 
present in a small number (Mueller et al., 2004). This type of inflammatory response where hydrophic 
degeneration and a lichenoid pattern is seen is usually associated with autoimmune disorders such as 
systemic and discoid lupus erythematosus, pemphigus and bullous pemphigoid (Scott, 1982). Although 
the histological changes resemble those of systemic lupus erythematosus, no other signs of systemic 
lupus erythematosus is seen as hemograms, urine analysis antinuclear antibody titers (ANA) appears to 
be normal in dogs affected by SLO compared to dogs affected by systemic lupus erythematosus (Mueller 
et al., 2000). 
 
During the last decade there has been an increased incidence of Gordon setters affected by SLO, in 
Norway. Pedigrees from 56 of these cases could be traced back to a common ancestor. During the same 
period, Gordon setters at an age of 1-2 years, that abruptly started to shed their black hair without 
normal regrowth, was observed. A study made in Norway suggests that SLO and black hair follicular 
dysplacia in Gordon setters may be pathogenetically related. The cutaneous affections is similar to those 
described in the human disease alopecia areata, which is an autoimmune disease, where 10-44% of the 
patients have nail involvements such as longitudinal ridging and thickening to friability and shedding 
(Bohnhorst J. Ö et al., 2001). 
 
The etiology of this condition is unknown. Diet and prior drug exposure can’t be excluded as disease 
causing factors (Scott et al., 1995). Treatments with omega-3 and omega-6 fatty acids have shown to 
have a positive effect for clinical improvement (Bergvall, 1997), yet treatment with trental 
(pentoxyphyllin) and tetracycline or doxyckline in combination with niacinamid have also been successful 
(Öhlen, Bergvall, 1999) (Mueller, 2003). If the affected dog doesn’t respond to the treatment, the next 
choice of treatment would be immunosuppressive drugs such as glucocorticoids (Mueller, 2003). In a 
long term observation study, where one crossbred pointer dog affected of SLO were treated with 
mechanical treatment such as cutting and filing of the nails , the trimming appeared to minimize the 
chances of further traumatic damage to the already affected nails (Verde & Basurco 2000). 
 
3. Material and method  
3.1 Study material 
Blood samples from 110 giant schnauzers and 10 bearded collies with different kinds of claw problems 
were collected. Of these 120 samples, 31 giant schnauzer samples and 10 bearded collies samples were 
analysed in this study, also included in this study were 79 giant schnauzers samples that were already 
analysed by Maria Wilbe in a previous study (Wilbe et al., submitted). 
 
3.2 Diagnostic criteria 
Dogs within this study were classified according to their claw problems. The classifications were based on 
a questionnaire that each owner had completed, except from 14 giant schnauzer owners that could not 10 
 
be reached. These dogs had different claw problems and were grouped as unclassified claw problems, 
UCP. The classification of the claw problems were made according to following criteria: 
E: claw fracture one claw one time 
EK: claw fracture less or no more than two times, with deviant claw quality, eventually secondary caused 
claw infections 
ÅK: returning claw fractures three times or more, with deviant claw quality, eventually secondary caused 
claw infections 
ÅI: returning primary claw infections on many claws, with no visible claw injury 
SLO: symmetrical lupoid onychodystrophy  
PEC or other tumor: squamous cells carcinoma or other tumor 
UCP: unclassified claw problems 
 
3.3 Extraction of DNA 
Genomic DNA was extracted from 200μL EDTA blood using QIAGEN DNA mini kit (QIAmp DNA Mini and 
Blood Mini Handbook 11/2007). The concentrations of the DNA were measured with nano-drop 
spectrophotometer.  
 
3.4 PCR amplification 
The genomic DNA was diluted with distilled water to a final concentration between 15-25ng/ L. For each 
dog the DNA sequences containing DLA-DRB1, DLA-DQA1 and DLA-DQB1 were amplified. Different 
primers were used to obtain amplification specific DLA fragments, see Table 1. T7 tailed primers were 
used to label the PCR products. 2 L DNA were mixed with a 18 L reaction mix containing: distilled 
water, 1 x PCR buffer, MgCl2 at a final concentration of 1,5mM, forward primer at a final concentration of 
10 M, reverse primer at a final concentration of 10 M, dNTP at a final concentration of 20mM and 
ampliTaq at a final concentration of 5U/ L. A touchdown PCR protocol was used for all amplifications to 
avoid amplification of nonspecific sequences. The PCR had a start temperature of 95° for 15 min, 
followed by 14 cycles of 30s at 95°C , 1 min annealing at 62°C (DRB1), 54°C (DQA1), 73°C (DQB1) reduced 
by 0,5°C for each cycle and 1 min elongation at 72°C. Thereafter, 20 cycles at 95°C for 30s followed by 1 
min at 55°C (DRB1), 47°C (DQA1), 60°C (DQB1), followed by 72°C for 1 min and at last 10 min at 72°C. 5μL 
of the PCR product were run on a 2% agarose gel, to determine whether the PCR reaction was successful. 
 
Table 1. Sequence for T7 and primers used for amplification of DLA- DRB1, DQA1 and DQB1. 
Primer  Primer sequence  Size 
DLA-DRB1 F  CCGTCCCCACAGCACATTC  303bp 
DLA-DRB1 R  T7-TGTGTCACACACCTCAGCACCA   
DLA-DQA1 F  TAAGGTTCTTTTCTCCCTCT  345bp 
DLA-DQA1 R  T7-GGACAGATTCAGTGAAGAGA   
DLA-DQB1 F  T7-CTCACTGGCCCGGCTGTCTC  300bp 
DLA-DQB1 R  CACCTCGCCGCTGCAACGTG   
T7  TAATACGACTCACTATAGGG   
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3.5 Purifying the PCR product and nucleotide sequence analysis 
The products from the PCR reactions were purified. For this, an ExoSAP reaction mix was used. 2 μL of 
the ExoSAP reaction mix were put into each wells on the PCR plate and the incubation time for ExoSAP 
was: 37°C for 1h and 85°C for 15min. 
 
To dilute the PCR product, 70 μL distilled water was added to each well. 3 μL of the PCR product were 
transferred to a new PCR plate and 3 μL T7 at a concentration of 5M were added to each well. As all PCR 
products were labelled with T7, which was used as a sequence primer. 12 μL distilled H2O were added to 
each well for further dilution. The PCR plates were sent to Uppsala Genome Center for sequencing. 
 
3.6 Data analysis 
Match Tools and Match Tools Navigator (Applied Biosystems), were used to analyse the sequence data. 
The sequences were first analyzed in Match Tools Navigator where the sequences were compared to a 
consensus sequence. Each polymorphic site was manually corrected. After the sequences were analyzed 
in Match Tools Navigator the sequences were compared in Match Tool to an already existing library 
consisting of different known alleles. The program then matched the sequence to the closest matching 
allele. 
 
3.7 Statistical analysis 
All samples were classified into controls or cases. The cases and controls were categorized into groups 
according to the presence of a certain haplotype, genotype or DQB1/DQA1/DRB1 allele. The total 
numbers of cases versus controls in every group were calculated. The frequencies were calculated for 
each group. The cases were also categorized according to classification and presence of a certain 
haplotype. The total number in each group was calculated and frequencies were calculated (see Table 2-
13). 
 
Statistical analysis was performed using a 2x2 contingency table. Calculations and results are presented 
in a table when the presence or absence of certain haplotype, genotype or DLA allele differentiated 
more than or 10 % between the case group and the control group. The number of cases where a specific 
DLA haplotype, genotype or allele were present and absent were calculated and compared with the 
number of controls with the same DLA haplotype, genotype or allele. Odds ratio, Relative risk and p-
values were calculated. Statistical analyses were calculated using Vassar Stats 
(http://faculty.vassar.edu/lowry/VassarStats.html) 
 
Relative risk was used to determine the risk for developing the disease if carrying a certain haplotype, 
genotype or DLA allele. The relative risk describe how much greater risk the exposed group have for 
developing the disease compared to the non exposed group. The relative risk can be calculated from 
following formula: 
RR = [a/ (a+b)] / [c/(c+d)] 
A relative risk > 1 is equal to an increased risk of developing disease if a certain haplotype, genotype or 
DLA allele is present and a relative risk < 1 is equal to a decreased risk for developing the disease if a 
certain haplotype, genotype, DLA allele is present, also called protective factor. 
 
Odds ratio is calculated from odds. The odds of an outcome can be described as the probability that an 
outcome does occur divided with the probability that the outcome does not occur. The odds of an 
outcome in the exposed group and the odds of an outcome in the unexposed group can be described as:  
odds exp = [a/ (a+b)] / [b/ (a+b)] = a/b 12 
 
odds unexp = [c/(c+d)] / [d/(c+d)] = c/d 
 
The odds ratio defines the ratio between the odds, and can be calculated: 
OR= (a/b)/ (c/d) = ad/bc 
(http://radiology.rsna.org/content/230/1/12) 
 
The definition of p-value is the probability to obtain a result that differ as much as or the same as the 
result we would expect if the null hypothesis was true. P-value was used to decide if the association was 
statistical significant i.e. did not arose by chance. At a p-value < 0, 05 is the null hypothesis is rejected 
and the result show statistical significance. 
 
Χ
2- test were to see that the result were statistically significant and did not arose by chance. For the Χ
2- 
test, 95% confidence interval and Yates values, which is corrected for continuity, were used. 
 
4. Results 
Classification, haplotype and genotype for each dog within this study are shown in supplementary Table 
1. 
 
4.1 Data analysis 
 
4.1.1 Haplotype frequency 
In this study, ten different haplotypes were found in the giant schnauzer breed. Three haplotypes 
(DRB1*00101/DQA1*00101/DQB1*00201, DRB1*00601/DQA1*00401/DQB1*01303 and 
(DRB1*01301/DQA1*00301/DQB1*00501) were common, with a frequency of > 15%, whereas seven 
haplotypes were less common with a frequency of <15%. The frequency of haplotype 
DRB1*00101/DQA1*00101/DQB1*00201 was higher in the case group compared to the control group 
(control group 15% versus the case group 26, 9%). The frequency of haplotype 
DRB1*01301/DQA1*00101/DQB1*00201 (case group 5% versus control group 15%) and haplotype 
DRB1*01301/DQA1*00301/DQB1*00501 (case group 13, 1% versus control group 25%) were higher in 
the control group compared to the case group (see Table 2).  
 
Five different haplotypes were found in bearded collie. Two haplotypes were more common 
(DRB1*01801/DQA1*00101/DQB1*00802 and DRB1*01801/DQA1*00101/DQB1*00201) with a 
frequency of > 15%, whereas three haplotypes were less common with a frequency of <15%. Two 
haplotypes occurred in a higher frequency in the case group compared to the control group, haplotype 
DRB1*01801/DQA1*00101/DQB1*00802 (case group 40% versus control group 20%) and haplotype 
DRB1*1801/DQA1*00101/DQB1*00201 (case group 60% versus control group 40%) (see Table 3). 
 
The haplotype frequencies according to classification are shown in Table 10. Group X consists of group 
EK, ÅK, ÅI and SLO. Haplotype DRB1*00101/DQA1*00101/DQB1*00201 is more frequent occurring in 
dogs with SLO (50%) and dogs classified in the X group (28%) compared to the control group (15%). 
Haplotype DRB1*01201/DQA1*00101/DQB1*00201 is more common in dogs classified in the ÅI group 
(60%) compared to the control group (11, 7%). Haplotype DRB1*02301/DQA1*00301/DQB1*00501 is 
more frequent occurring in the PEC/tumor and ÅK group, both has a frequency of 16, 7% compared to 
the control group with a frequency of 5%. 
 
Table 2. Haplotype frequency for giant schnauzer in the total population and classified as controls or cases. 13 
 
Haplotype 
DRB1/DQA1/DQB1 
 Case and control (%) 
(220) 
 Case (%)                   
(160) 
 Control (%)              
(60) 
00101/00101/00201    23,6% (52)   26,9% (43)  15% (9) 
00601/00401/01303  20, 9% (46)   21,3% (34)  20% (12) 
00901/00101/008011  1,82 % (4)  0,63% (1)  5% (3) 
01201/00101/00201  13,6% (30)  14,4% (23)  11,7% (7) 
01301/00101/00201  7,73% (17)  5,0 % (8)  15% (9) 
01301/00301/00501  16,4% (36)  13,1% (21)  25% (15) 
02301/00301/00501  9,55% (21)  11,3% (18)  5% (3) 
01501/00601/00301  1,82% (4)  1,88% (3)  1,67% (1) 
01501/00601/02201  4,09% (9)  5,0% (8)  1,67% (1) 
02001/00401/01303  0,45% (1)  0,63% (1)  0 
 
Table 3. Haplotype frequency for bearded collies in the total population and classified as controls or cases. 
Haplotype 
DRB1/DQA1/DQB1 
 Case and controls (%) 
(20) 
Case (%) 
(10) 
Controls (%) 
(10) 
01801/00101/00802  30% (6)  40% (4)  20% (2) 
01801/00101/00201  50% (10)  60% (6)  40% (4) 
01501/00601/00301  5% (1)  0  10% (1) 
00201/00901/00101  5% (1)  0  10% (1) 
01501/00601/02301  10% (2)  0  20% (2) 
 
Table 4. Haplotype frequencies in the total population and according to classification in giant schnauzer  
Haplotype 
DRB1/DQA1/DQB1 
Case & 
controls % 
(220) 
Control % 
(60) 
E %         
(8) 
EK % 
(44) 
ÅK %       
(42) 
ÅI % 
(10) 
SLO% 
(14) 
PEC/tumour
%             
(24) 
UCP% 
(28) 
X %            
(100) 
00101/00101/00201  23,6%               
(52) 
15%                 
(9) 
25% 
(2) 
31,8% 
(14) 
19%     
(8) 
10% 
(1) 
50% 
(7) 
20,8%          
(5) 
28,6% 
(8) 
28% 
(28) 
00601/00401/01303  20,9%             
(46) 
20%            
(12) 
0,13% 
(1) 
29,5% 
(13) 
14.3% 
(6) 
10% 
(1) 
14,3% 
(2) 
37,5%          
(9) 
25% 
(7) 
17% 
(17) 14 
 
00901/00101/08011  1,82 %          
(4) 
5%                      
(3) 
0,13% 
(1) 
0  0  0  0  0  0  0 
01201/00101/00201  13,6%               
(30) 
11,7%                  
(7) 
0,13% 
(1) 
13,6% 
(6) 
14,3% 
(6) 
60% 
(6) 
7,14% 
(1) 
12,5%           
(3) 
3,57% 
(1) 
18% 
(18) 
01301/00101/00201  7,73%                
(17) 
15%                     
(9) 
0  2,27% 
(1) 
4,76% 
(2) 
10% 
(1) 
7,14% 
(1) 
8,33%           
(2) 
3,57% 
(1) 
5%        
(5) 
01301/00301/00501  16,4%               
(36) 
25%                   
(15) 
0  13,6% 
(6) 
17,5% 
(7) 
0  14,3% 
(2) 
0  21,4% 
(6) 
15% 
(15) 
02301/00301/00501  9,54%          
(21) 
5%                        
(3) 
0,13% 
(1) 
4,55% 
(2) 
16,7% 
(7) 
10% 
(1) 
0  16,7%          
(4) 
17,9% 
(5) 
8%      
(8) 
01501/00601/00301  1,82%                   
(4) 
1,67%                 
(1) 
0,13% 
(1) 
2,27% 
(1) 
0  0  0  4,17%                
(1) 
0  1%        
(1) 
01501/00601/02201  4,09%                      
(9) 
1,67%                  
(1) 
0,13% 
(1) 
2,27% 
(1) 
11,9% 
(5) 
0  7,14% 
(1) 
0  0  7%       
(7) 
02001/00401/01303  0,45%                   
(1) 
0  0  0  2,38% 
(1) 
0  0  0  0  1%       
(1) 
 
4.1.2 Allele frequency 
In giant schnauzer, eight different DRB1 alleles were found. Three alleles were more common 
(DRB1*00101, DRB1*00601 and DRB1*01301) with a frequency of > 15%, whereas five were less 
common with a frequency of <15%. The allele DRB1*00101 occurred in a higher frequency in the case 
group compared to the control group (control group 15% versus case group 26, 9%). The frequency of 
allele DRB1*1301 were higher in the control group compared to the case group (control group 40% 
versus case group 18, 1%) (see Table 5). 
 
Four different DQA1 alleles were found. One allele was less common (DQA1*00601), with a frequency of 
< 15%, whereas the other three alleles were more common with a frequency of >15%. There was no 
DQA1 allele that occurred in a higher/lower frequency (difference of more than 10%) in the case group 
compared to the control group (see Table 6). Six different DQB1 alleles were found. Three alleles were 
more common (DQB1*00201, DQB1*01303 and DQB1*00501) with a frequency of >15%, whereas three 
alleles were less common, with a frequency of <15%. There was no DQB1 allele that occurred in a 
higher/lower frequency (difference of more than 10%) in the case group compared to the control group 
(see Table 7) 
 
In bearded collie, three DRB1 alleles were found. Allele DRB1*1801 was very common (80%) compared 
to the other two alleles DRB1*00201 (5%) and DRB1*01501 (15%). Three DQA1 alleles were found. Allele 
DQA1*00101 was very common (80%) compared to the other two alleles DQA1*00901 (5%) and 
DQA1*00601 (15%). Both the DRB1*01801 allele and DQA1*00101 allele were present at a frequency of 
100% in the case group compared to 60% in the control group (see Table 8 and 9). Five different DQB1 
alleles were found, two alleles (DQB1*00201 and DQB1*00802) were more common with a frequency 
>15%, the other three were less common with a frequency of <15%. Both DQB1 alleles DQB1*00201 and 
DQB1*00802 were more common among the cases compared to the controls (see Table 10). 
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Table 5. Frequency of DRB1 alleles for total population, cases and controls in giant schnauzer. 
Allele DRB1  Case and control % 
(220) 
Control % 
(60) 
Case % 
(160) 
00101  23,6% (52)  15% (9)  26,9% (43) 
00601  20,9% (46)  20% (12)  21,3% (34) 
01301  24,1% (53)  40% (24)  18,1% (29) 
00901  1,82% (4)  5% (3)  0,625% (1) 
01201  13,6% (30)  11,7% (7)  14,4% (23) 
02301  9,54% (21)  5% (3)  11,3% (18) 
01501  5,91% (13)  3,33% (2)  6,88% (11) 
02001  0,45% (1)  0  0,625% (1) 
 
Table 6. Frequency of DQA1 alleles for total population, cases and controls in giant schnauzer. 
Allele DQA1  Control and case % 
(220) 
Control % 
(60) 
Case % 
(160) 
00101  46,8% (103)  46,7% (28)  46,9% (75) 
00401  21,4% (47)  20% (12)  21,9% (35) 
00301  25,9% (57)  30% (18)  24,4% (39) 
00601  5,91% (13)  3,33% (2)  6,87% (11) 
 
Table 7. Frequency of DQB1 alleles for total population, cases and controls in giant schnauzer. 
Allele DQB1  Control and case % 
(220) 
Control % 
(60) 
Case % 
(160) 
00201  45% (99)  41,7% (25)  46,3% (74) 
01303  21,4% (47)  20% (12)  21,9% (35) 
00501  25,9% (57)  30% (18)  24,4% (39) 
08011  1,82% (4)  5% (3)  0,625% (1) 
00301  1,82% (4)  1,67% (1)  1,88% (3) 16 
 
02201  4,09% (9)  1,67% (1)  0 
 
Table 8. Frequency of DRB1 alleles for total population, cases and controls in bearded collie. 
Allele DRB1  Control and case % 
(20) 
Control % 
10st 
Case % 
(10)  
01801  80% (16)  60% (6)  100% (10) 
00201  5% (1)  10% (1)  0 
01501  15% (3)  30% (3)  0 
   
Table 9. Frequency of DQA1 alleles for total population, cases and controls in bearded collie. 
Allele DQA1  Control and case % 
(20) 
Control % 
(10) 
Case % 
(10) 
00101  80% (16)  60% (6)  100% (10) 
00901  5% (1)  10% (1)  0 
00601  15% (3)  30% (3)  0 
 
Table 10. Frequency of DQB1 alleles for total population, cases and controls in bearded collie. 
Allele DQB1  Control and case % 
(20) 
Control % 
(10) 
Case % 
(10) 
00201  50% (10)  40% (4)  60% (6) 
00802  30% (6)  20% (2)  40% (4) 
02301  10% (2)  20% (2)  0 
00301  5% (1)  10% (1)  0 
00101  5% (1)  10% (1)  0 
 
4.1.3 Genotype frequency 
In giant schnauzer, thirty genotypes were found. Every genotype occurred in a frequency less than 15% 
and there was no significant difference between the frequency in the case group and the control group 
(see supplementary Table 2). 
 
In bearded collie, four different genotypes were found.  The genotype 
DRB1*01801/DQA1*00101/DQB1*00802-DRB2*01801/DQA2*00101/DQB2*00202 occurred in a higher 17 
 
frequency (80%) in the case group (all classified in the SLO group), compared to the control group (40%) 
(see supplementary Table 3). 
  
4.2 Statistical analyses 
Odds ratio, relative risk and p-values were calculated for those results where the frequency between the 
case and control group differentiated more than 10%, to see whether those results indicate an increased 
risk or a protective role for developing claw problems and to determine if results were statistically 
significant. 
 
In giant schnauzer, statistical analyses of haplotype DRB1*00101/DQA1*00101/DQB1*00201 showed a 
relative risk of 1,79 an odds ratio of 2,08 and a p-value of 0,095.  The allele DRB1*00101 had a relative 
risk of 1,79 an odds ratio of 2,08 and a p-value of 0,095. Statistical analyses of haplotype 
DRB1*01301/DQA1*00301/DQB1*00501 showed a relative risk of 0,525 and odds ratio of 0,453 and a p-
value of 0,055. The allele DRB1*01301 had a relative risk of 0,453 an odds ratio of 0,332 and a p-value of 
0,0014 (Table 11).  
 
Table 11. Statistical analyses of haplotypes and alleles in giant schnauzer were the frequency between the case and control 
group differentiated more than 10%. 
  Case   
(No) 
Total Case 
(No) 
Control 
(No) 
Total 
Control 
(No) 
RR  OR  p-value 
Haplotype 
DRB1*00101/DQA1*00101/DQB1*00201 
43  160  9  60  1,79  2,08  0,095 
Haplotype 
DRB1*01301/DQA1*00301/DQB1*00501 
21  160  15  60  0,525  0,453  0,055 
Haplotype 
DRB1*01301/DQA1*00101/DQB1*00201 
8  160  9  60  0,333  0,298  N.A 
Allele DRB1*00101  43  160  9  60  1,79  2,08  0,095 
Allele DRB1*01301  29  160  24  60  0,453  0,332  0,001 
 
Statistical analyses of the X group, which consists of cases classified in the EK, ÅK ÅI and SLO group, 
showed that the haplotype DRB1*00101/DQA1*00101/DQB1*00201 had a relative risk of 1,87 an odds 
ratio of 2,20 and a p-value of 0,090 (see Table 12). 
 
Table 12. Statistical analyses of haplotypes in giant schnauzer were the frequency between the classified case and control group 
differentiated more than 10%. 
  Case       
(No) 
Total Case 
(No) 
Control  
(No) 
Total 
Control 
(No) 
RR  OR  p- value 
Haplotype  
DRB1*00101/DQA1*00101/DQB1*00201 
7 
SLO 
14 SLO  9  60  3,33  5,67  N.A 
Haplotype  
DRB1*00101/DQA1*00101/DQB1*00201 
28 X  100 X  9  60  1,87  2,20  0,090 
Haplotype 
DRB1*01201/DQA1*00101/DQB100201 
6 ÅI  10 ÅI  7  60  5,14  11,4  N.A 
Haplotype  7 ÅK  42 ÅK  3  60  3,33  3,8  N.A 18 
 
DRB1*02301/DQA1*00301/DQB1*00501 
 
Statistical analyses in bearded collie showed that haplotype DRB1*01801/DQA1*00101/DQB1*00201 
had a relative risk of 1,5 an odds ratio of 2,25 and a p-value of 0,65. Allele DQB1*00201 had a relative 
risk of 1,5 an odds ratio of 2,25 and a p-value of 0,65 (see Table 13). 
 
Table 13. Statistical analyses of haplotypes, genotypes and alleles in bearded collie were the frequency between the case and 
control group differentiated more than 10%. 
  Case 
(No) 
Total Case 
(No) 
Control 
(No) 
Total 
Control 
(No) 
RR  OR  p-
value 
Haplotype 
DRB1*01801/DQA1*00101/DQB1*00802 
4 
SLO 
10 SLO  2  10  2  2,67  N.A 
Haplotype 
DRB1*01801/DQA1*00101/DQB1*00201 
6 
SLO 
10 SLO  4  10  1,5  2,25  0,65 
Genotype DRB1*01801/DQA1*00101/DQB11*00802-  
DRB1*01801/DQA1*00101/DQB1*00201 
4  5  2  5  2  6  N.A 
Allele DRB1*01801  10  10  6  10  1,67  infinity  N.A 
Allele DQA1*00101  10  10  6  10  1,67  infinity  N.A 
Allele DQB1*00201  6  10  4  10  1,5  2,25  0,65 
Allele DQB1*00802  4  10  2  10  2  2,67  N.A 
 
5. Discussion and Conclusions 
The aim with this study was to establish the nucleotide sequence of the highly polymorph DLA loci DLA-
DRB1, DLA-DQA1 and DLA-DQB1 and to determine whether certain haplotypes, genotypes or DLA- alleles 
can be associated with a higher risk of development of symmetrical lupoid onychodystrophy. 
 
In giant schnauzer the haplotypes DRB1*01301/DQA1*00101/DQB1*00201 and 
DRB1*01301/DQA1*00301/DQB1*00501 occurred in a higher frequency in the control group compared 
to the case group. Statistical analyses indicate that haplotype DRB1*01301/DQA1*00301/DQB1*00501 
may be protective against the development of claw problems, although this result is not statistically 
significant (p-value=0,055). Allele DRB1*01301 occurred in a higher frequency in the control group (40%) 
compared to the case group (18,1%) with a relative risk of 0,453, odds ratio of 0,332 and a p-value of 
0,001, these results show that allele DRB1*01301 is a protective allele against development of claw 
problems and importantly these results are statistically significant. In a recent study, a protective DLA- 
DRB1/DQA1/DQB1 haplotype (DRB1*01301/DQA1*00301/DQB1*00501) for developing canine 
lymphocytic thyroiditis in giant schnauzer have been identified (Wilbe et al. submitted). The protective 
haplotype found in this study haplotype DRB1*01301/DQA1*00301/DQB1*00501 agrees with that 
result. In both studies giant schnauzers where examined and allele DRB1*01301 and haplotype 
DRB1*01301/DQA1*00301/DQB1*00501 were shown to be protective against both claw problems and 
hypothyroidism. An explanation to this may be that canine lymphocytic thyroiditis is known to 
sometimes predispose development claw infections and slough of the claw as a result, thus may dogs 
with a protective DLA haplotype or allele against development of lymphocytic thyroiditis also be 
protective against development of claw problems. 
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In giant schnauzer, haplotype DRB1*00101/DQA1*00101/DQB1*00201 occurred in a higher frequency in 
the case group (26,9%) compared to the control group (15%). The allele DRB1*00101 also occurred in a 
higher frequency in the case group (26,9%) compared to the control group (15%). This indicated that the 
haplotype DRB1*00101/DQA1*00101/DQB1*00201 and allele DRB1*00101 may increase the risk for 
developing claw problems, however since the p-value is not <0,05 those results are not statistically 
significant. Since neither the allele DQA1*00101 nor the allele DQB1*00201 had a higher frequency in 
the case group compared to the control group it is more likely that it is the allele DRB1*00101 that may 
give rise to an increased risk for developing claw problems, than the haplotype 
DRB1*00101/DQA1*00101/DQB1*00201.  
The haplotype DRB1*00101/DQA1*00101/DQB1*00201 occurred in 50% of the SLO cases compared to 
15% of the control group. In the X group, which consists of cases classified in the EK, ÅK ÅI and SLO 
group, statistical analyses indicates that the haplotype DRB1*00101/DQA1*00101/DQB1*00201 may be 
a risk haplotype, although this result is not statistically significant (p-value=0,095 and OR=2,08). 
DRB1*00101 or haplotype DRB1*00101/DQA1*00101/DQB1*00201 may be one of the risk factors for 
development of different claw problems and SLO. There may be a majority of unknown risk factors that 
are involved in the development of SLO, but these results imply that the DRB1*00101 or haplotype 
DRB1*00101/DQA1*00101/DQB1*00201 may be one of them. 
 
In bearded collie, the haplotypes DRB1*01801/DQA1*00101/DQB1*00802 and 
DRB1*01801/DQA1*00101/DQB1*00202 and the genotype DRB1*01801/DQA1*00101/DQB1*00802-
DRB2*01801/DQA1*00101/DQB2*00202 group occur in a higher frequency in the case group compared 
to the control group. Statistical analyses indicate that haplotype 
DRB1*01801/DQA1*00101/DQB1*00201 and allele DQB1*00201 may give rise to a higher risk of 
developing SLO in bearded collie, however those result show no statistical significance (p-value=0,65). In 
an unpublished study concerning genetic association between DLA class II and SLO in Gordon setter, the 
same predisposing haplotype (DRB1*01801/DQA1*00101/DQB1*00802) that was found in this study has 
been found with statistically significant results (Personal message Maria Wilbe). This finding strengthen 
the suspicion that dogs with haplotype DRB1*01801/DQA1*00101/DQB1*00802 is predisposed to 
develop SLO. 
 
Amino acid substitutions caused by DLA polymorphism located in the MHC molecules three hyper 
variable regions (HVR) cause structural changes in the MHC binding pockets as the amino acids have 
different charge and size. The structural changes in the HVR may influence peptides ability to bind to the 
MHC molecule but also the T cell recognition. MHC associated autoimmunity could be due to activation 
of peripheral T cells that have escaped the negative selection process in thymus and have to high affinity 
to self antigens, or those that have to low affinity for self antigens but cross react to external stimuli such 
as viruses and bacteria which imitate self antigens. The stability of the MHC molecule bound to the 
antigen may also be a part in autoimmunity, if the MHC molecule is very unstable when bound to 
antigen there is a risk that T cells will escape the negative selection process in thymus since the 
interaction between the MHC molecule and the peptide is to short, and T cells with to high affinity for 
self antigens will not be detected and eliminated (Brand et al., 2005).   
 
The result obtained in this study support the supposition that SLO may be an autoimmune disease. As 
both protective and predisposing DLA class II alleles and haplotypes, have been found. The reasons that 
some of the result is not statistically significant may be that some of the result arose by chance or it may 
be a result of too few analysed samples, further studies with more individuals may give an answer to 
this. The information about risk and protective DLA-alleles, haplotypes and genotypes can be used in 20 
 
future breeding practice in order to obtain healthier dogs, but also give more understanding about SLO 
and other autoimmune diseases. 
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Supplementary Table 1. Sample ID, classification, haplotype and genotype for each dog in this study. 
      DRB1  DQA1  DQB1  DRB1  DQA1  DQB1  Haplotye  Genotype 
Sample ID  Breed  Status  Allele 1  Allele 1  Allele 1  Allele 2  Allele 2  Allele 2     
2.45.130  GS  ÅI  01301  00101  00201  01201  00101  00201  4, 2  24 
2.45.140  GS  ÅI  01201  00101  00201  01201  00101  00201  2, 2  26 
2.45.196  GS  ÅI  01201  00101  00201  01201  00101  00201  2, 2  26 
2.45.32  GS  ÅK  00101  00101   00201   00101  00101  00201  1, 1  1 
2.45.113  GS  ÅK  00101  00101  00201  00101  00101  00201  1, 1  1 
2.45.13  GS  ÅK  00601  00401   01303   01201   00101   00201   3, 2  13 
2.45.399  GS  ÅK  00601  00401  01303  01501  00601  02201  3, 8  15 
2.45.488  GS  ÅK  01301  00301  00501  01501  00601  02201  5, 8  16 
2.45.91  GS  ÅK  01301  00301  00501  01501  00601  02201  5, 8  16 
2.45.239  GS  ÅK  01301  00301  00501  01501  00601  02201  5, 8  16 
2.45.78  GS  ÅK  01301  00301  00501  01201  00101   00201  5, 2  18 
2.45.47  GS  ÅK  01301  00101  00201  01301  00101  00201  4, 4  23 
2.45.491  GS  ÅK  01201  00101   00201  02301  00301  00501  2, 6  27 
2.45.158  GS  ÅK  01201  00101   00201  02301  00301  00501  2, 6  27 
2.45.163  GS  ÅK  01201  00101   00201  02301  00301  00501  2, 6  27 
2.45.452  GS  ÅK  02301  00301  00501  01501  00601  02201  6, 8  28 
2.45.274  GS  ÅK  00601  00401   01303   02001  0401  01303  3, 9  32 
2.45.231  GS  ÅK  00101  00101  00201   01301  00301  00501  1, 5  4 
2.45.378  GS  ÅK  00101  00101  00201  02301  00301  00501  1, 6  5 
2.45.82  GS  ÅK  00601  00401   01303   01301  00301  00501  3, 5  8 
2.45.180  GS  ÅK  00601  00401   01303   01301  00301  00501  3, 5  8 
2.45.331  GS  ÅK (ÅI)  00601  00401   01303   02301  00301  00501  3, 6  14 
2.45.119  GS  ÅK (ÅI)  00101  00101  00201   01201  00101   00201  1, 2  2 
2.45.254  GS  control  00101  00101  00201   00101  00101  00201   1, 1  1 
2.45.1  GS  control  00101  00101   00201   00101   00101   00201   1, 1  1 
2.45.66  GS  control  00601  00401   01303   00901   00101   08011   3, 7  10 
2.45.48   GS  control  00601  00401   01303   01301  00301  00501  3, 5  8 
2.45.92  GS  control  01301  00301  00501  01501  00601  02201  5, 8  16 
2.45.63   GS  control  01301  00301  00501  01301  00101  00201  5, 4  17 
2.45.87  GS  control  01301  00301  00501  01301  00101   00201  5, 4  17 
2.45.219  GS  control  01301  00301  00501  01201  00101   00201  5, 2  18 
2.45.171   GS  control  01301  00301  00501  01301  00301  00501  5, 5  19 
2.45.221  GS  control  01301  00301  00501  01301  00301  00501  5, 5  19 
2.45.79   GS  control  00101  00101  00201   01201  00101   00201  1, 2  2 
2.45.36  GS  control  00101   00101   00201   01201  00101   00201  1, 2  2 
2.45.161   GS  control  01301  00301  00501  01501  00601  00301  5, 10  20 
2.45.89  GS  control  0901  00101   08011   00901   00101   08011   7, 7  22 
2.45.70  GS  control  01301  00101   00201  01301  00101   00201  4, 4  23 
2.45.64  GS  control  01201  00101   00201  01201  00101   00201  2, 2  26 
2.45.51   GS  control  01201  00101   00201  02301  00301  00501  2, 6  27 
2.45.54   GS  control  02301  00301  00501  02301  00301  00501  6,6  29 
2.45.245  GS  control  00101   00101   00201   00601  00401   01303   1, 3  3 
2.45.232  GS  control  00101  00101  00201   01301  00301  00501  1, 5  4 
2.45.33   GS  control  00601  00401   01303   01301  00301  00501  3, 5  8 
2.45.80   GS  control  00601  00401   01303   01301  00301  00501  3, 5  8 
2.45.102  GS  control  00601  00401   01303   01301  00301  00501  3, 5  8 
2.45.93  GS  control  00601  00401   01303   01301  00301  00501  3, 5  8 24 
 
2.45.99   GS  control  00601  00401   01303   01301  00101  00201  3, 4  9 
2.45.177  GS  control  00601  00401   01303   01301  00101  00201  3, 4  9 
2.45.53  GS  control  00601  00401   01303   01301  00101  00201  3, 4  9 
2.45.61  GS  control  00601  00401   01303   01301  00101  00201  3, 4  9 
2.45.77  GS  control  00601  00401   01303   01301  00101   00201  3, 4  9 
2.45.109  GS  control   00101  00101  00201  01201  00101   00201  1, 2  2 
2.45.75  GS  E  00101  00101  00201  00101  00101  00201  1, 1  1 
2.45.367  GS  E  00601  00401  01303  00901  00101  08011  3, 7  10 
2.45.189  GS  E  01201  00101   00201  02301  00301  00501  2, 6  27 
2.45.379  GS  E  01501  00601  00301  01501  00601  02201  10, 8  31 
2.45.267  GS  EK  00101  00101  00201  00101  00101  00201  1, 1  1 
2.45.351/396  GS  EK  00601  00401   01303   00601  00401   01303   3, 3  12 
2.45.458  GS  EK  01301  00301  00501  01201  00101   00201  5, 2  18 
2.45.401  GS  EK  01301  00301  00501  01201  00101   00201  5, 2  18 
2.45.490  GS  EK  00101  00101  00201  01201  00101   00201  1, 2  2 
2.45.49  GS  EK  00101  00101  00201  01201  00101   00201  1, 2  2 
2.45.84  GS  EK  01201  00101   00201  01201  00101   00201  2, 2  26 
2.45.487  GS  EK  00101  00101  00201  00601  00401  01303  1, 3  3 
2.45.350  GS  EK  00101  00101  00201  00601  00401  01303  1, 3  3 
2.45.18  GS  EK  00101   00101   00201   00601   00401   01303   1, 3  3 
2.45.207  GS  EK  00101  00101  00201  00601  00401  01303  1, 3  3 
2.45.24  GS  EK  00101  00101  00201   00601  00401   01303   1, 3  3 
2.45.529  GS  EK  01501  00601  00301  01501  00601  02201  10, 8  31 
2.45.455  GS  EK  00101  00101  00201  01301  00301  00501  1, 5  4 
2.45.101  GS  EK  00101  00101  00201   01301  00301  501  1, 5  4 
2.45.334  GS  EK  00101  00101  00201  02301  00301  00501  1,6  5 
2.45.5  GS  EK  00101  00101  00201   02301  00301  00501  1, 6  5 
2.45.440  GS  EK  00101  00101  00201  01301  00101  00201  1, 4  6 
2.45.513  GS  EK  00601  00401  01303  01301  00301  00501  3, 5  8 
2.45.329  GS  EK  00601  00401   01303   01301  00301  00501  3, 5  8 
2.45.489  GS  PEC  00601  00401  01303   00601  00401  01303   3, 3  12 
2.45.530  GS  PEC  00601  00401  01303  01201  00101   00201  3, 2  13 
2.45.527  GS  PEC  00601  00401  01303  02301  00301  00501  3, 6  14 
2.45.191  GS  PEC  00101  00101  00201   01201  00101   00201  1, 2  2 
2.45.433  GS  PEC  01301  00101  00201  02301  00301  00501  4, 6  25 
2.45.56  GS  PEC  01201  00101   00201  02301  00301  00501  2, 6  27 
2.45.421  GS  PEC  00101  00101  00201  00601  00401  01303  1, 3  3 
2.45.407  GS  PEC  00101  00101  00201  01501  00601  00301  1, 10  7 
2.45.159  GS  PEC (ÅK)  00101  00101  00201   02301  00301  00501  1, 6  5 
2.45.7  GS  PEC (EK)  00601  00401   01303   00601  00401   01303   3, 3  12 
2.45.336  GS  PEC/tomour  00101  00101  00201  01301  00101  00201  1, 4  6 
2.45.344  GS 
PEC/tomour 
(EK)  00601  00401  01303   00601  00401  01303   3, 3  12 
2.45.528  GS  SLO  00101  00101  00201  00101  00101  00201  1, 1  1 
2.45.519  GS  SLO  00101  00101  00201  00101  00101  00201  1, 1  1 
2.45.524  GS  SLO  00601  00401  01303  00601  00401   01303  3, 3  12 
2.45.328  GS  SLO  01301  00301  00501  01501  00601  02201  5, 8  16 
2.45.411  GS  SLO  00101  00101  00201  01201  00101   00201  1, 2  2 
2.45.39  GS  SLO  00101  00101  00201   01301  00301  00501  1, 5  4 
2.45.504  GS  SLO  00101  00101  00201  01301  00101  00201  1, 4  6 
2.45.457  GS  UCP   00601  00401  01303  02301  00301  00501  3, 6  14 25 
 
2.45.249  GS  UCP   00101  00101  00201  00101  00101  00201  1, 1  1 
2.45.108  GS  UCP   01301  00301  00501  01201  00101   00201  5, 2  18 
2.45.2  GS  UCP  00101  00101  00201  01301  00301  00501  1, 5  4 
2.45.104  GS  UCP   00101  00101  00201  00101  00101  00201  1, 1  1 
2.45.11  GS  UCP   00101  00101  00201  00101  00101  00201  1, 1  1 
2.45.144  GS  UCP   00601  00401  01303  00601  00401  01303  3, 3  12 
2.45.97  GS  UCP   01301  00301  00501  02301  00301  00501  5, 6  21 
2.45.17  GS  UCP   00601  00401  01303  01301  00301  00501  3, 5  8 
2.45.508  GS  UCP   00601  00401  01303  02301  00301  00501  3, 6  14 
2.45.466  GS  UCP   01301  00101  00201  02301  00301  00501  4, 6  25 
2.45.226  GS  UCP   01301  00301  00501  02301  00301  00501  5, 6  21 
'2.45.40  GS  UCP   00101  00101  00201  00601  00401  01303  1, 3  3 
2.45.60  GS  UCP   00601  00401  01303  01301  00301  00501  3, 5  8 
1.6.4  BC  control  01801  00101  00201  01801  00101  00802  1, 2  32 
1.6.7  BC  control  01801  00101  00201  01801  00101  00802  1, 2  32 
1.6.2  BC  control  01501  00601  00301  01501  00601  02301  5, 4  33 
1.6.3  BC  control  00201  00901  00101  01501  00601  02301  3, 4  34 
1.6.6  BC  control  01801  00101  00201  01801  00101  00201  1, 1  35 
1.6.1  BC  SLO  01801  00101  00201  01801  00101  00802  1, 2  32 
1.6.10  BC  SLO  01801  00101  00201  01801  00101  00802  1, 2  32 
1.6.8  BC  SLO  01801  00101  00201  01801  00101  00802  1, 2  32 
1.6.9  BC  SLO  01801  00101  00201  01801  00101  00802  1, 2  32 
1.6.5  BC  SLO  01801  00101  00201  01801  00101  00201  1, 1  35 
         
 
           
        Allele  Allele  Allele         
    Haplotypes GS  Code  DRB1  DQA1  DQB1         
      1  00101   00101  00201         
      2  01201  00101  00201         
      3  00601    00401     01303          
      4  01301  00101  00201         
      5  01301  00301  00501         
      6  02301  00301  00501         
      7  00901  00101  08011         
      8  01501  00601  002201         
      9  02001  0401  01303         
      10  01501  00601  00301         
           
 
         
        Allele  Allele  Allele         
    Haplotypes BC  Code  DRB1  DQA1  DQB1         
      1  01801  00101  00802         
      2  01801  00101  00201         
      3  00201  00901  00101         
      4  01501  00601  02301         
      5  01501  00601  00301         
     
 
               
      Code  DRB1  DQA1  DQB1  DRB2  DQA2  DQB2   
    Genotype GS  1  00101   00101  00201  00101   00101  00201   26 
 
      2  00101  00101  00201  01201  00101  00201   
      3  00101  00101  00201  00601    00401     01303    
      4  00101  00101  00201  01301  00301  00501   
      5  00101  00101  00201  02301  00301  00501   
      6  101  101  00201  01301  101  00201   
      7  101  101  00201  01501  00601  00301   
      8  601  401  1303  1301  301  501   
      9  601  401  1303  1301  101  201   
      10  00601  00401  01303  00901  101  008011   
      12  601  401  1303  601  401  1303   
      13  00601  00401  01303  01201  101  00201   
      14  601  401  1303  2301  301  501   
      15  00601  00401  01303  01501  00601  02201   
      16   1301  301   501   1501   601   2201    
      17  1301   301   501   1301  00101   201    
      18  1301   301   501   1201  00101   201    
      19  1301  301  501  1301  301  501   
      20  1301  301  501  1501  601  301   
      21  01301  00301  00501  02301  00301  00501   
      22  901  00101   8011   901   00101   8011    
      23   1301  00101   201   1301   00101   201    
      24  1301  101  201  1201  101  201   
      25  01301  101  00201  02301  00301  00501   
      26  1201  101  201  1201  101  201   
      27  1201  101  201  2301  301  501   
      28  02301  00301  00501  01501  00601  02201   
      29  2301  301  501  2301  301  501   
      31  01501  00601  00301  01501  00601  002201   
      32  601  401  1303  2001  401  1303   
       
 
             
    Genotype BC  Code  DRB1  DQA1  DQB1  DRB2  DQA2  DQB2   
      32  01801  101  00201  01801  101  00802   
      33  01501  00601  00301  01501  00601  02301   
      34  00201  00901  101  01501  00601  02301   
      35  01801  101  00201  01801  101  00201   
 
 
Supplementary Table 2. Genotype frequency and genotype code for giant schnauzer in the total population and classified as 
controls or cases. 
Genotype 
DRB1/DQA1/DQB1*DRB2/DQA2/DQB2 
Genoty
pe 
code 
Case and control  
% (110) 
 
Control 
% (30) 
 
Case  
% (80) 
00101/00101/00201*00101/00101/00201  1  10% (11)  6,67% (2)  11,3% (9) 
00101/00101/00201*01201/00101/00201  2  7,27% (8)  10% (3)  6,25% (5) 
00101/00101/00201*00601/00401/01303  3  7,27% (8)  3,33% (1)  8,75% (7) 27 
 
00101/00101/00201*01301/00301/00501  4  5,45% (6)  3,33% (1)  6,25% (5) 
00101/00101/00201*02301/00301/00501  5  3,64% (4)  0  5% (4) 
00101/00101/00201*01301/00101/00201  6  2,73% (3)  0  3,75% (3) 
00101/00101/00201*01501/00601/00301  7  0,91% (1)  0  1,25% (1) 
00601/00401/01303*01301/00301/00501  8  10% (11)  12,9%(5)  7,5% (6) 
00601/00401/01303*01301/00101/00201  9  4,55% (5)  16,7%(5)  0 
00601/00401/01303*00901/00101/08011  10  1,82% (2)  3,33%(1)  1,25% (1) 
00601/00401/01303*00601/00401/01303  12  5,45% (6)  0  7,5% (6) 
00601/00401/01303*01201/00101/00201  13  1,82% (2)  0  2,5% (2) 
00601/00401/01303*02301/00301/00501  14  3,64% (4)  0  5% (4) 
00601/00401/01303*01501/00601/02201  15  0,91% (1)  3,33% (1)  0 
01301/00301/00501*01501/00601/02201  16  4,55% (5)  3,33% (1)  5% (4) 
01301/00301/00501*01301/00101/00201  17  1,82% (2)  3,33% (1)  1,25% (1) 
01301/00301/00501*01201/00101/00201  18  4,55% (5)  3,33% (1)  5% (4) 
01301/00301/00501*01301/00301/00501  19  1,82% (2)  6,67% (2)  0 
01301/00301/00501*01501/00601/00301  20  0,91% (1)  3,33% (1)  0 
01301/00301/00501*02301/00301/00501  21  1,82% (2)  0  2,5% (2) 
00901/00101/08011*00901/00101/08011  22  0,91% (1)  3,33% (1)  0 
01301/00101/00201*01301/00101/00201  23  1,82% (2)  3,33% (1)  1,25% (1) 
01301/00101/00201*01201/00101/00201  24  0,91% (1)  0  1,25% (1) 
01301/00101/00201*02301/00301/00501  25  1,82% (2)  0  2,5% (2) 
01201/00101/00201*01201/00101/00201  26  3,64% (4)  3,33% (1)  3,75% (3) 
01201/00101/00201*02301/00301/00501  27  5,45% (6)  3,33% (1)  6,25% (5) 
01201/00101/00201*01501/00601/02201  28  0,91% (1)  0  1,25% (1) 
02301/00301/00501*02301/00301/00501  29  0,91% (1)  3,33% (1)  0 28 
 
01501/00601/00301*01501/00601/02201  31  1,82% (2)  0  2,5% (2) 
00601/00401/01303*2001/00401/01303  32  0,91%(1)  0  1,25% (1) 
 
Supplementary Table 3. Genotype frequency and genotype code for bearded collies in the total population and classified as 
controls or cases. 
Genotype 
DRB1/DQA1/DQB1*DRB2/DQA2/DQB2 
Genotype 
code 
Case and control 
% (10) 
Control 
% (5) 
Case 
% (5) 
01801/00101/00802*01801/00101/00201  32  60% (6)  40% (2)  80% (4) 
01501/00601/00301*01501/00601/02301  33  10% (1)  20% (1)  0 
00201/00901/00101*01501/00601/02301  34  10% (1)  20% (1)  0 
01801/00101/00201*01801/00101/00201  35  20% (2)  20% (1)  20% (1) 
 